信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT
ROBUST GROWTH ACHIEVED IN PRODUCT REVENUE IN THE YEAR AND THE FOURTH QUARTER OF 2025

This announcement is made by Innovent Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

For the full year of 2025, the total product revenue amounted to approximately RMB11.9 billion, representing a robust year-over-year growth of approximately 45%. Notably, in the fourth quarter of 2025, the Company recognized inventory price adjustments for products previously distributed to channels at original prices. This adjustment was primarily driven by the inclusion of six new drugs in the 2026 National Reimbursement Drug List (NRDL). Under the above stated circumstances, the Company achieved the total product revenue of approximately RMB3.3 billion in the fourth quarter of 2025, representing a strong year-over-year growth rate of over 60% and sustaining strong growth momentum.

The year 2025 marked a historic milestone as the Company's product revenue surpassed the RMB10 billion threshold for the first time. This achievement signifies the successful execution and excellent results of our "dual-engine growth and global innovation" strategy. The Company consolidated its leadership with 13 products in oncology, and synergies across the oncology portfolio have become increasingly evident; major products including TYVYT® (sintilimab injection) sustained growth, while newly-launched oncology products also contributed meaningful incremental revenue. Meanwhile, the Company successfully expanded its commercial footprint into the chronic disease area. Leveraging the vast unmet medical needs, the competitiveness of our innovative products, and a scientific, high-efficiency commercialization strategy, our general biomedicine portfolio has demonstrated significant growth momentum. Specifically, mazdutide, SINTBILO® (tafolecimab injection) and SYCUME® (teprotumumab N01 injection) have continued accelerating uptake, contributing as crucial new pillars of growth. Furthermore, PECONDLE® (picankibart injection) as another anchor asset in general biomedicine portfolio, has received approval for launch at the end of 2025.

The year 2025 performance further validates the Company's exceptional commercial execution and sustainable business model. Looking ahead to 2026, the Company will continue to leverage core strengths – strategic foresight, operational agility, and high-efficiency execution – to drive sustainable growth through our dual-engine growth strategy in oncology and general biomedicine. The Company also continues to enhance its operational efficiency as we strive to become a China's top-tier biopharmaceutical company with comprehensive excellence.

Concurrently, the Company is marching into a new chapter of global innovation. We are making pivotal progress in global clinical development for our pipeline, represented by next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies in oncology, as well as next-generation assets in cardiovascular and metabolic (CVM), autoimmune, and ophthalmology diseases. These advancements will continue to unlock long-term growth potential, positioning us towards our vision of "becoming a global premier biopharmaceutical company."

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
February 4, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.